Cost Effectiveness of Teplizumab for Prevention of Type 1 Diabetes Among Different Target Patient Groups
Author:
Publisher
Springer Science and Business Media LLC
Subject
Public Health, Environmental and Occupational Health,Health Policy,Pharmacology
Link
https://link.springer.com/content/pdf/10.1007/s40273-020-00962-y.pdf
Reference42 articles.
1. Klinke DJ. Extent of beta cell destruction is important but insufficient to predict the onset of type 1 diabetes mellitus. PLoS One [Internet]. 2008;pp. 3. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2147725/. Accessed 21 Dec 2019.
2. Statistics About Diabetes|ADA [Internet]. 2019. https://www.diabetes.org/resources/statistics/statistics-about-diabetes. Accessed 21 Nov 2019.
3. Chiang JL, Kirkman MS, Laffel LM, Peters AL. Type 1 diabetes through the life span: a position statement of the American Diabetes Association. Diabetes care. 2014;37:2034–54.
4. Tao B, Pietropaolo M, Atkinson M, Schatz D, Taylor D. Estimating the cost of type 1 diabetes in the US: a propensity score matching method. PLoS One. 2010;5:e11501.
5. Hua X, Carvalho N, Tew M, Huang ES, Herman WH, Clarke P. Expenditures and prices of antihyperglycemic medications in the United States: 2002-2013. Jama. 2016;315:1400–2.
Cited by 8 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Reply to the Letter to the Editor, Endocrine Practice for "Role of Teplizumab, a Humanized Anti-CD3 Monoclonal Antibody, in Managing Newly Diagnosed Type 1 Diabetes: An Updated Systematic Review and Meta-Analysis”;Endocrine Practice;2024-07
2. Teplizumab: promises and challenges of a recently approved monoclonal antibody for the prevention of type 1 diabetes or preservation of residual beta cell function;Expert Review of Clinical Immunology;2023-11-12
3. Teplizumab Therapy to Delay the Onset of Type 1 Diabetes;Cardiology in Review;2023-05-10
4. Teplizumab: type 1 diabetes mellitus preventable?;European Journal of Clinical Pharmacology;2023-04-01
5. Teplizumab – preventative approaches to type 1 diabetes mellitus;Practical Diabetes;2023-03
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3